Tremfya Phase III Maintenance Study Results Presented by J&J for Ulcerative Colitis Treatment

J&J, Johnson & Johnson, Tremfya, guselkumab, Phase III trial, maintenance study, ulcerative colitis, inflammatory bowel disease, treatment, efficacy, safety, remission.

AstraZeneca’s COVID-19 Antibody Treatment Shows Promising Results in Immunocompromised Individuals

AstraZeneca, COVID-19, antibody treatment, immunocompromised individuals, enhanced protection, clinical trials, monoclonal antibodies, virus neutralization, immune response.